Analysis of bone marrow cell morphological abnormalities in patients treated with methotrexate

DOI Web Site
  • MORIYAMA Yasunori
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • SUGIHARA Takahiro
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • MORIOKA Yukino
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • TAWA Takumi
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • TAHARA Aya
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • DOTEUCHI Yasushi
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital
  • TAKAHASHI Shizu
    Department of Clinical Laboratory, Japanese Red Cross Matsuyama Hospital

Bibliographic Information

Other Title
  • メソトレキセート使用患者における骨髄形態異常の解析
  • メソトレキセート シヨウ カンジャ ニ オケル コツズイ ケイタイ イジョウ ノ カイセキ

Search this article

Abstract

<p>Methotrexate (MTX) is a key drug in the treatment of rheumatoid arthritis, but it sometimes causes hematopoietic disorders with morphological abnormalities of bone marrow cells, which may be difficult to distinguish from myelodysplastic syndrome (MDS). Originally, bone marrow biopsy should not be carried out in the initial diagnosis, but in practice, samples are occasionally obtained and submitted for analysis. However, since there is little detailed information in the literature on how much morphological abnormalities appear in the initial diagnosis, we analyzed the morphology of bone marrow cells from 12 patients treated with MTX. As a result, seven patients were found to have more than one lineage of morphological abnormalities, and three of them had more than 10% of ring sideroblasts. If the history of MTX use is not known, there is a risk that such finding would lead to the diagnosis of MDS; therefore, a detailed check of drugs taken that may affect results is necessary at the time of diagnosis.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top